Evidence map›Paper›PMID 26056590›Full record

ReviewMolecular and cellular therapies2014

Magnetic nanoparticles for oligodendrocyte precursor cell transplantation therapies: progress and challenges.

Stuart I Jenkins, Humphrey H P Yiu, Matthew J Rosseinsky, Divya M Chari

Abstract readReview
In one paragraph

Review in Molecular and cellular therapies, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stuart I JenkinsCellular and Neural Engineering Group, Institute for Science and Technology in Medicine Keele University, Stoke-on-Trent, Staffordshire ST5 5BG UK.
Humphrey H P YiuSchool of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, EH14 4AS UK.
Matthew J RosseinskyDepartment of Chemistry, University of Liverpool, Liverpool, L69 7ZD UK.
Divya M ChariCellular and Neural Engineering Group, Institute for Science and Technology in Medicine Keele University, Stoke-on-Trent, Staffordshire ST5 5BG UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligodendrocyte precursor cells (OPCs) have shown high promise as a transplant population to promote regeneration in the central nervous system, specifically, for the production of myelin - the protective sheath around nerve fibers. While clinical trials for these cells have commenced in some areas, there are currently key barriers to the translation of neural cell therapies. These include the ability to (a) image transplant populations in vivo; (b) genetically engineer transplant cells to augment their repair potential; and (c) safely target cells to sites of pathology. Here, we review the evidence that magnetic nanoparticles (MNPs) are a 'multifunctional nanoplatform' that can aid in safely addressing these translational challenges in neural cell/OPC therapy: by facilitating real-time and post-mortem assessment of transplant cell biodistribution, and biomolecule delivery to transplant cells, as well as non-invasive 'magnetic cell targeting' to injury sites by application of high gradient fields. We identify key issues relating to the standardization and reporting of physicochemical and biological data in the field; we consider that it will be essential to systematically address these issues in order to fully evaluate the utility of the MNP platform for neural cell transplantation, and to develop efficacious neurocompatible particles for translational applications.

Indexed as

Cell therapyIron oxideLabelingMagnetic targetingNeural cellOPCTrackingUptake

Identifiers

PMID26056590
PMCPMC4452053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.